Associated Genetic Biomarkers
CD247 is altered in 0.01% of all cancers with glioblastoma and undifferentiated pleomorphic sarcoma having the greatest prevalence of alterations .
The most common alterations in CD247 are CD247-DDR2 Fusion (0.00%) and CD247-NTRK1 Fusion (0.02%) .
CD247 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain CD247 status as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
Trials with CD247 status in the inclusion eligibility criteria most commonly target acute lymphoblastic leukemia .
The most frequent alteration to serve as an inclusion eligibility criterion is CD247 Expression .
Taa-specific t cells is the most frequent therapy in trials with CD247 as an inclusion criteria .
Significance of CD247 in Diseases
Acute Lymphoblastic Leukemia +
CD247 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CD247 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) .
Enteropathy-Associated T-Cell Lymphoma +
CD247 is an inclusion criterion in 1 clinical trial for enteropathy-associated T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD247 status and enteropathy-associated T-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.